A Phase 1b/2a, Open-label, Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon in Combination With Ribavirin in Treatment-naive Subjects With Genotype 1 Hepatitis C.

Trial Profile

A Phase 1b/2a, Open-label, Randomized, Safety, Tolerability, Dose Finding, Pharmacokinetic/Pharmacodynamic, and Preliminary Efficacy Study of Subcutaneous Hanferon in Combination With Ribavirin in Treatment-naive Subjects With Genotype 1 Hepatitis C.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Apr 2014

At a glance

  • Drugs Interferon alpha-2b; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors HanAll Biopharma
  • Most Recent Events

    • 22 Apr 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrial.gov record.
    • 19 Jun 2012 Phase IIa testing is ongoing, according to a HanAll BioPharma media release.
    • 02 Apr 2012 Planned End Date changed from 1 Jan 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top